FDA / 2026
FDA concerns with unapproved GLP-1 drugs used for weight loss
FDA concerns with unapproved GLP-1 drugs used for weight loss — U.S. FDA (2026), cited in PeptideAgent's Retatrutide, Semaglutide evidence records.
Open original sourceSOURCE METADATA
What this record represents.
- Publisher
- U.S. FDA
- Evidence type
- FDA
- Publication year
- 2026
- Source ID
- fda-unapproved-glp1
WHERE THIS IS CITED